VAS
WVE icon

Vestmark Advisory Solutions’s Wave Life Sciences WVE Stock Holding History

Vestmark Advisory Solutions’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,421
Closed -$517K – 1430
2025
Q4 		$517K Buy
+30,421
New +$309K 0.01% 990

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
GP
GSK plc London $602M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vestmark Advisory Solutions's WVE Position: Q1 2026 in Review

Vestmark Advisory Solutions sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 30,421 shares — an estimated $517K sold.

Vestmark Advisory Solutions first reported a position in WVE in Q4 2025 and held it in 1 quarter. The position peaked at $517K in Q4 2025. 232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Vestmark Advisory Solutions reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Vestmark Advisory Solutions sold 30,421 Wave Life Sciences shares in Q1 2026, an estimated $517K.
  • Vestmark Advisory Solutions first reported a position in Wave Life Sciences in Q4 2025 and held it in 1 quarter.
  • Vestmark Advisory Solutions's Wave Life Sciences position peaked at $517K in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.